Table 5.
Mexico | Argentina | France | Peru | |||||
---|---|---|---|---|---|---|---|---|
CSP Type |
Clin (n = 28) |
Env (n = 26) |
Overall (54) |
Clin (n = 27) |
Env (n = 2) |
Overall (n = 29) |
Clin (n = 4) |
Clin (n = 3) |
t01 | 14.2% | 11.5% | 12.9% | 7.4% | 6.8% | 66.6% | ||
t02 | 14.2% | 11.5% | 12.9% | 11.1% | 10.3% | |||
t03 | 3.5% | 11.5% | 7.4% | 25.9% | 50% | 27.5% | 25% | |
t04A | 25% | 53.8% | 38.8% | 40.7% | 50% | 41.3% | 75% | 33.3% |
t06B | 28.5% | 14.8% | ||||||
tT10 | 11.5% | 5.5% | ||||||
t13 | 10.7% | 5.5% | ||||||
t14 | 3.5% | 1.8% | 3.7% | 3.4% | ||||
t25 * | 3.7% | 3.4% | ||||||
t26 * | 7.4% | 6.8% |
Clin, clinical isolate; Env, environmental isolate; * CSP type t25 and t26 are new types.